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corr e spondence
Estrogen Therapy and Coronary-Artery Calcification
To the Editor: In their article on the Women’s 
Health Initiative Coronary-Artery Calcium Study 
(WHI-CACS), Manson et al. (June 21 issue)1 pro-
vide insight into another mechanism by which 
estrogen therapy reduces coronary heart disease 
(CHD) in women who have undergone hysterec-
tomy and who initiate such therapy close to meno-
pause.2 The authors’ findings further support the 
hypothesis that early initiation of such therapy 
has a beneficial effect.3 
For women under the age of 60 years, scien-
tific evidence indicates that estrogen therapy is 
as efficacious in reducing CHD as are other pri-
mary prevention therapies, such as lipid-lowering 
drugs and aspirin, and is more effective in reduc-
ing total mortality.4 For women in this age group, 
estrogen therapy has a risk profile that is no 
greater than that of other medications used for 
primary prevention of CHD in women.4 Studies 
by the WHI, other randomized trials, and obser-
vational studies (including the WHI observational 
study) show significant trends toward a greater 
benefit with respect to total mortality and CHD 
with a longer duration of estrogen therapy.2,4
WHI-CACS was similar to the Estrogen in the 
Prevention of Atherosclerosis Trial5 in provid-
ing mechanistic evidence for a role of estrogen 
therapy in the prevention of CHD in postmeno-
pausal women. WHI not only has confirmed the 
known benefits from observational studies but 
also has clearly shown the relative safety of es-
trogen therapy under randomized, controlled con-
ditions in women under the age of 60 years 
(Table 1).2,4
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Table 1. Effect of Therapy with Conjugated Equine  
Estrogen on Major Outcomes in Women under the Age 
of 60 Years.*
Event Estrogen as Compared with Placebo
Percent 
Difference 
Absolute Difference  
in No. of Events  
per 10,000 Women  
per Year of Therapy
Death −29 −11
Coronary heart  
disease
−37 −11
Stroke −11 −2
New-onset diabe-
tes mellitus
−12 −14
Bone fracture −30 −56
Breast cancer† −18 −8
Venous thrombo-
embolism‡
+37 +4
* Data are from the Women’s Health Initiative. 
† The reduction was 33% among women whose compli-
ance with the estrogen-therapy regimen was at least 
80% (risk ratio, 0.67; 95% confidence interval, 0.47 to 
0.97).
‡ This category includes deep-vein thrombosis and pul-
monary embolism.
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To the Editor: With regard to the report by 
Manson et al. on the effect of estrogen therapy 
on calcium scores in a subgroup of middle-aged 
women from the WHI trial,1 we feel it is some-
what unfortunate to state that the data provide 
some reassurance that estrogen therapy may not 
be harmful. Conclusions with regard to clinical 
outcome should be drawn only from trials that 
are designed and powered to address clinical 
events. If a surrogate end point is presented, it 
should have an established association with a 
clinical outcome and be obtained in a trial with 
optimal methodology.
The WHI trial was not designed to address 
the effect of estrogen on calcium scores, which 
accounts for the lack of a baseline calcium score 
and explains why modifiable risk factors (e.g., 
smoking) and the use of concomitant medica-
tion were not routinely scored during follow-up. 
Moreover, in low-risk subjects, the prognostic ef-
fect of calcium scores is far from established.2,3 
In our opinion, the reported effects of estrogen 
therapy on calcium scores should be considered 
as hypothesis-generating. We look forward to 
the clinical follow-up after computed tomogra-
phy has been performed to provide insight into 
the possible prognostic value of these findings.
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To the Editor: Manson et al. convincingly show 
that estrogen-only replacement therapy, when 
started between the ages of 50 and 59 years in 
postmenopausal women who have undergone hys-
terectomy, reduced coronary-artery calcification. 
This article and the accompanying editorial by 
Mendelsohn and Karas1 provide us with valuable 
arguments when translating evidence into clini-
cal practice. Since bone represents the body’s 
largest storage compartment for calcium, and es-
trogen-only replacement therapy increased bone 
mass,2 the antiresorptive effects of estrogen may 
have contributed to reduced vascular calcifica-
tion by reducing the efflux of calcium from bone. 
Were bone markers or measurements of bone 
mineral density available for these women, and 
were such measures correlated with calcification 
scores?
As the authors mention, the vascular effects 
of estrogens are complex and occur at multiple 
levels, including gene expression of bone-related 
factors.1 Osteoprotegerin represents an estrogen-
responsive cytokine with skeletal and vascular 
effects,3 and deletion of this protein in mice leads 
to osteoporosis and vascular calcification.4 Were 
serum osteoprotegerin levels assessed in this 
study? In our opinion, this cohort represents a 
pivotal opportunity to shed further light on the 
mechanisms underlying the osteoporosis–vascu-
lar calcification syndrome.
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The authors reply: Hodis and Mack state that 
for women under the age of 60 years who have 
undergone hysterectomy, estrogen reduces CHD 
and is more effective in reducing total mortality 
than are other primary prevention therapies. 
Moreover, they assert that the WHI has “clearly 
shown” the relative safety of estrogen therapy in 
women under 60. We disagree that the WHI con-
clusively showed that estrogen therapy reduces 
either CHD or total mortality in younger women. 
Although younger women receiving estrogen ap-
peared to have a more favorable balance of ben-
efits and risks than did older women, interaction 
tests according to age showed only borderline 
significance.1 
In addition, it remains unclear whether with 
prolonged treatment any coronary benefits of es-
trogen therapy in women under the age of 60 
years would persist at older ages, when coronary 
events become more frequent. We do believe that 
the WHI findings on estrogen therapy in young-
er women, combined with the low absolute rates 
of vascular events in this age group, provide 
some reassurance to recently menopausal women 
who are considering hormone therapy for the 
short-term treatment of menopausal symptoms. 
However, in light of other risks, we believe that 
hormone therapy should not be used for the 
prevention of CHD or other chronic diseases.
We agree with Brouwer and colleagues that 
conclusions with regard to clinical outcomes 
should be drawn from trials designed and pow-
ered to address clinical events. However, we did 
not state that the data provide reassurance that 
estrogen therapy may not be harmful. Indeed, 
we noted explicitly that “other risks and benefits 
of treatment must be considered,” even though 
estrogen is “unlikely to have an adverse effect on 
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4.
the risk of coronary events among women who 
have recently undergone menopause.” However, 
coronary-artery calcium scores do appear to im-
prove prediction of the risk of CHD, even in asymp-
tomatic persons at relatively low risk for CHD.2
Finally, we concur with Hofbauer et al. that 
the mechanisms underlying the relationship be-
tween estrogen and vascular calcification, includ-
ing the possible role of antiresorptive effects of 
estrogen, warrant further study. We do not have 
data on serum osteoprotegerin levels, and we have 
data on bone mineral density for only a small 
number of women, so we cannot address the 
correlations proposed by Hofbauer et al. Notably, 
a postmortem study of coronary arteries sug-
gested that estrogen therapy was associated with 
both a smaller plaque area and reduced calcium 
content.3 Coronary-artery calcium scores in WHI-
CACS were strongly correlated with traditional 
risk factors for CHD, including smoking, hyper-
tension, hypercholesterolemia, and diabetes, sug-
gesting a strong correlation with atheromatous 
plaque burden. We hope that future analyses of 
data from WHI-CACS and other studies will fur-
ther elucidate the mechanistic basis for the rela-
tionships we observed.
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